Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization

摘要: Since heterozygous familial hypercholesterolemia (HeFH) is a disease that exposes the individual from birth onwards to severe with development of early cardiovascular disease, clear consensus on management this in young patients necessary. In Belgium, panel paediatricians, specialists (adult) lipid management, general practitioners and representatives FH patient organization agreed following common recommendations. 1. Screening for HeFH should be performed only children older than 2 years when has been identified or suspected (based genetic test clinical criteria) one parent.2. The diagnostic procedure includes, as first step, establishment diagnosis parents. If precondition satisfied, low-density-lipoprotein cholesterol (LDL-C) levelabove 3.5 mmol/L (135 mg/dL) child predictive differentiating affected non-affected children. 3. A low saturated fat diet started after years, under supervision dietician nutritionist.4. pharmacological treatment, using statins line drugs, usually 10 if LDL-C levels remain above 5 (190 mg/dL), 4 (160 presence causative mutation, family history risk factors. objective reduce by at least 30% between 14 and, thereafter, reach less 3.4 (130 mg/dL).CONCLUSION: aim statement achieve more consistent identification treatment Belgium.